Prognostic Impact of Baseline Serum Creatinine in Patients with Advanced High-Grade Serous Ovarian Carcinoma Undergoing Neoadjuvant Chemotherapy

Objective: To evaluate whether baseline serum creatinine is associated with survival outcomes in patients with advanced high-grade serous ovarian carcinoma undergoing neoadjuvant chemotherapy. Methods: We retrospectively analyzed 77 patients treated between 2009 and 2018. Patients were stratified by baseline serum creatinine levels (<84 vs. ≥84 μmol/L), and survival outcomes were assessed using Kaplan-Meier analysis. Results: No statistically significant differences in progression-free or overall survival were observed between groups. A trend toward shorter OS in the elevated creatinine group did not reach significance. Conclusion: Baseline serum creatinine was not found to be a statistically significant prognostic marker in this cohort. These results highlight the need for adjusted analyses incorporating established prognostic factors in future research.